SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme
35A Boulevard Joseph II, L-1840 Luxembourg
Sub: Update on intimation dated 3rd November, 2021 on termination of Stock Purchase and Merger Agreement ("the SPMA") with Avenue Therapeutics Inc.
Dear Sir/Madam,
In reference to the above mentioned intimation, the Company hereby notifies that the SPMA entered between InvaGen Pharmaceuticals Inc. ("InvaGen"), USA, wholly owned step down subsidiary of the Company, and Avenue Therapeutics Inc ("Avenue") has been terminated with effect from 1st November 2021.
However, the 'Stockholders Agreement' dated 12th November 2018 between InvaGen, Avenue and other stockholders remains in force; and InvaGen will continue to hold shares in Avenue.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 24826000 F +91 22 24826120 Wwww.cipla.com E-mailcontactus@cipla.comCorporate Identity Number L24239MH1935PLC002380
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cipla Ltd. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 17:15:00 UTC.
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).